These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
134 related items for PubMed ID: 17994286
1. Outcome of type III Gaucher disease on enzyme replacement therapy: review of 55 cases. Davies EH, Erikson A, Collin-Histed T, Mengel E, Tylki-Szymanska A, Vellodi A. J Inherit Metab Dis; 2007 Nov; 30(6):935-42. PubMed ID: 17994286 [Abstract] [Full Text] [Related]
2. Long-term hematological, visceral, and growth outcomes in children with Gaucher disease type 3 treated with imiglucerase in the International Collaborative Gaucher Group Gaucher Registry. El-Beshlawy A, Tylki-Szymanska A, Vellodi A, Belmatoug N, Grabowski GA, Kolodny EH, Batista JL, Cox GF, Mistry PK. Mol Genet Metab; 2017 Nov; 120(1-2):47-56. PubMed ID: 28040394 [Abstract] [Full Text] [Related]
3. Enzyme replacement therapy in pediatric patients with Gaucher disease: what should we use as maintenance dosage? Brunel-Guitton C, Rivard GE, Galipeau J, Alos N, Miron MC, Therrien R, Mitchell G, Lapierre G, Lambert M. Mol Genet Metab; 2009 Feb; 96(2):73-6. PubMed ID: 19083253 [Abstract] [Full Text] [Related]
4. Enzyme replacement therapy and bony changes in Egyptian paediatric Gaucher disease patients. El-Beshlawy A, Ragab L, Youssry I, Yakout K, El-Kiki H, Eid K, Mansour IM, Abd El-Hamid S, Yang M, Mistry PK. J Inherit Metab Dis; 2006 Feb; 29(1):92-8. PubMed ID: 16601874 [Abstract] [Full Text] [Related]
5. Gaucher disease: studies of phenotype, molecular diagnosis and treatment. Rice EO, Mifflin TE, Sakallah S, Lee RE, Sansieri CA, Barranger JA. Clin Genet; 1996 Mar; 49(3):111-8. PubMed ID: 8737974 [Abstract] [Full Text] [Related]
6. Long term effects of enzyme replacement therapy in an Italian cohort of type 3 Gaucher patients. Sechi A, Deroma L, Dardis A, Ciana G, Bertin N, Concolino D, Linari S, Perria C, Bembi B. Mol Genet Metab; 2014 Nov; 113(3):213-8. PubMed ID: 25127542 [Abstract] [Full Text] [Related]
7. Cessation of enzyme replacement therapy in Gaucher disease. Grinzaid KA, Geller E, Hanna SL, Elsas LJ. Genet Med; 2002 Nov; 4(6):427-33. PubMed ID: 12509713 [Abstract] [Full Text] [Related]
9. Gaucher disease among Chinese patients: review on genotype/phenotype correlation from 29 patients and identification of novel and rare alleles. Choy FY, Zhang W, Shi HP, Zay A, Campbell T, Tang N, Ferreira P. Blood Cells Mol Dis; 2007 Nov; 38(3):287-93. PubMed ID: 17196853 [Abstract] [Full Text] [Related]
10. Report of the Spanish Gaucher's disease registry: clinical and genetic characteristics. Giraldo P, Pocoví M, Pérez-Calvo J, Rubio-Félix D, Giralt M. Haematologica; 2000 Aug; 85(8):792-9. PubMed ID: 10942924 [Abstract] [Full Text] [Related]
11. [A retrospective study on enzyme replacement therapy in patients with Gaucher disease]. Duan YL, Zhang YH, Zang Y, Shi HP, Zhang WM, Hu YM. Zhonghua Er Ke Za Zhi; 2006 Sep; 44(9):653-6. PubMed ID: 17217655 [Abstract] [Full Text] [Related]
13. Clinical and genetic studies of Japanese homozygotes for the Gaucher disease L444P mutation. Ida H, Rennert OM, Iwasawa K, Kobayashi M, Eto Y. Hum Genet; 1999 Sep; 105(1-2):120-6. PubMed ID: 10480365 [Abstract] [Full Text] [Related]
14. Enzyme replacement therapy for Gaucher disease in Australia. Goldblatt J, Szer J, Fletcher JM, McGill J, Rowell JA, Wilson M. Intern Med J; 2005 Mar; 35(3):156-61. PubMed ID: 15737135 [Abstract] [Full Text] [Related]
15. Successful Treatment of Gaucher Disease With Matched Sibling Hematopoietic Stem Cell Transplantation: A Case Report and Literature Review. Chavananon S, Sripornsawan P, Songthawee N, Chotsampancharoen T. J Pediatr Hematol Oncol; 2021 Nov 01; 43(8):e1153-e1155. PubMed ID: 33661172 [Abstract] [Full Text] [Related]
16. Imiglucerase low-dose therapy for paediatric Gaucher disease--a long-term cohort study. Heitner R, Arndt S, Levin JB. S Afr Med J; 2004 Aug 01; 94(8):647-51. PubMed ID: 15352589 [Abstract] [Full Text] [Related]
17. The appearance of newly identified intraocular lesions in Gaucher disease type 3 despite long-term glucocerebrosidase replacement therapy. Sawicka-Gutaj N, Machaczka M, Kulińska-Niedziela I, Bernardczyk-Meller J, Gutaj P, Sowiński J, Ruchała M. Ups J Med Sci; 2016 Aug 01; 121(3):192-5. PubMed ID: 27064303 [Abstract] [Full Text] [Related]
18. Transformation in pretreatment manifestations of Gaucher disease type 1 during two decades of alglucerase/imiglucerase enzyme replacement therapy in the International Collaborative Gaucher Group (ICGG) Gaucher Registry. Mistry PK, Batista JL, Andersson HC, Balwani M, Burrow TA, Charrow J, Kaplan P, Khan A, Kishnani PS, Kolodny EH, Rosenbloom B, Scott CR, Weinreb N. Am J Hematol; 2017 Sep 01; 92(9):929-939. PubMed ID: 28569047 [Abstract] [Full Text] [Related]
19. [Enzyme replacement therapy in Gaucher disease: monitoring visceral and bone changes with MRI]. Tóth J, Szücs FZ, Benkö K, Maródi L. Orv Hetil; 2003 Apr 20; 144(16):749-55. PubMed ID: 12778625 [Abstract] [Full Text] [Related]
20. Delayed growth and puberty in patients with Gaucher disease type 1: natural history and effect of splenectomy and/or enzyme replacement therapy. Kauli R, Zaizov R, Lazar L, Pertzelan A, Laron Z, Galatzer A, Phillip M, Yaniv Y, Cohen IJ. Isr Med Assoc J; 2000 Feb 20; 2(2):158-63. PubMed ID: 10804944 [Abstract] [Full Text] [Related] Page: [Next] [New Search]